Literature DB >> 6974215

Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression.

C D Mills, R J North, E S Dye.   

Abstract

It was shown that subcutaneous implantation of P815 tumor cells admixed with Corynebacterium parvum resulted in the emergence of a tumor that grew for 9-10 d and then regressed. The onset of tumor aggression was preceded by the substantial generation in the draining lymph node and spleen of T cells capable of specifically lysing P815 target cells in vitro. The finding that the magnitude of this cytolytic response was much greater than the cytolytic response to a control tumor that grew progressively is consistent with the hypothesis that the anti-tumor action of C. parvum is based on its capacity to augment the production of T cells sensitized to tumor-specific transplantation antigens. This adjuvant action of C. parvum was revealed by additional experiments in which irradiated, nonreplicating tumor cells were substituted for living tumor cells in the admixture. The results support the conclusion that the potentiated cytolytic response to subcutaneous injection of an admixture of irradiated tumor cells and C. parvum is responsible for the ability of this admixture to cause the regression of a test tumor growing at a distant site. Finally, it was shown that the failure of the therapeutic admixture to cause the regression of distant test tumors above a certain size was associated with a failure of the admixture to cause a potentiated, anti-tumor cytolytic response. We discussed the possibility that this failure was caused by the presence of a tumor-induced state of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974215      PMCID: PMC2186449          DOI: 10.1084/jem.154.3.621

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Quantitative assessment of cellular and humoral responses to skin and tumor allografts.

Authors:  T G Canty; J R Wunderlich
Journal:  Transplantation       Date:  1971-02       Impact factor: 4.939

2.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

Review 3.  Control of experimental contact sensitivity.

Authors:  H N Claman; S D Miller; P J Conlon; J W Moorhead
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

Review 4.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

5.  Possible roles of suppressor cells in immunologic tolerance.

Authors:  W O Weigle; D G Sieckmann; M V Doyle; J M Chiller
Journal:  Transplant Rev       Date:  1975

6.  Generation of cytotoxic T lymphocytes in vitro. VII. Suppressive effect of irradiated MLC cells on CTL response.

Authors:  F W Fitch; H D Engers; J C Cerottini; K T Bruner
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

7.  Mouse lymphocytes with and without surface immunoglobulin: preparative scale separation in polystyrene tissue culture dishes coated with specifically purified anti-immunoglobulin.

Authors:  M G Mage; L L McHugh; T L Rothstein
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

8.  In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor-bearing mice.

Authors:  F Takei; J G Levy; D G Kilburn
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

9.  T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.

Authors:  M J Berendt; R J North
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.

Authors:  P W Askenase; B J Hayden; R K Gershon
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  13 in total

1.  Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

Authors:  R J North; E S Dye
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

Review 2.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Frequency analysis of augmented CTL production associated with Corynebacterium parvum-induced tumour regression.

Authors:  T R Johnson; R J North
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

5.  Role of respiratory-burst products from polymorphonuclear leukocytes in the antitumor activity of Propionibacterium acnes vaccine.

Authors:  E A Murano; C S Cummins
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations.

Authors:  E S Dye; R J North; C D Mills
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

7.  Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.

Authors:  D L Hines
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour.

Authors:  A Digiacomo; R J North
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

9.  The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.